Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey. Reunion alleges that Mindset purposefully copied its psychedelic compound RE104 -a Novel Chemical Entity (NCE)- and presented it as novel to the USPTO while applying for IP coverage. 

See also: Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries

Reunion aims to enroll the original and sole inventor of its compound RE104, the company’s CSO Dr. Nathan Bryson, as an inventor on Mindset’s patent application as well as co-ownership on it, plus claims of inequitable conduct in the prosecution …

Full story available on